Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects

• Published in: Diabetes care Vol. 14; no. 4; pp. 302 - 307
• Main Authors: Haffner, S.M. (University of Texas Health Science Center, San Antonio), Tuttle, K.R, Rainwater, D.L
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.04.1991
• Subjects: administration & dosage; Adult; APOLIPOPROTEINS; Apolipoproteins - blood; Apoprotein(a); Biological and medical sciences; blood; blood glucose; Blood Glucose - metabolism; Blood Glucose Self-Monitoring; BLOOD PLASMA; BLOOD SUGAR; CHOLESTEROL; COLESTEROL; DIABETE; DIABETES; DIABETES MELLITUS; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Diabetes. Impaired glucose tolerance; drug therapy; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; FEMME; GLICEMIA; GLYCAEMIA; Glycated Hemoglobin; Glycated Hemoglobin A - metabolism; GLYCEMIE; HEALTH; HEALTH HAZARDS; HIGH DENSITY LIPOPROTEIN; HOMBRES; HOMME; Humans; Infusions, Intravenous; Insulin; Insulin - administration & dosage; Insulin - blood; Lipoprotein(a); LIPOPROTEINAS; LIPOPROTEINE; LIPOPROTEINS; Lipoproteins - blood; LOW DENSITY LIPOPROTEIN; Male; Medical sciences; MEN; metabolic studies; METABOLISM; METABOLISME; METABOLISMO; MUJERES; PLASMA SANGUIN; PLASMA SANGUINEO; SALUD; SANTE; TRIACYLGLYCEROLS; TRIGLICERIDOS; TRIGLYCERIDE; TRIGLYCERIDES; WOMEN; Endocrinopathy; Human; Risk factor; Insulin dependent diabetes; Cardiovascular disease; Lipids; Carbohydrate; Lipoprotein; Metabolism
• ISSN: 0149-5992; 1935-5548
• DOI: 10.2337/diacare.14.4.302

Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects. S M Haffner , K R Tuttle and D L Rainwater Department of Medicine, University of Texas Health Science Center, San Antonio 78284. Abstract OBJECTIVE: Recently, lipoprotein(a) [Lp(a)] has been identified as a major risk factor for coronary heart disease. There are few data available on the influence of metabolic control on plasma Lp(a) concentrations in subjects with insulin-dependent diabetes mellitus (IDDM), a group at high risk for coronary heart disease. RESEARCH DESIGN AND METHODS: We examined the effects of improved metabolic control on plasma lipid and lipoproteins and Lp(a) concentrations in 12 subjects before and after 21 days of tight metabolic control. RESULTS: Glycosylated hemoglobin declined from 8.4 to 6.9% (P less than 0.001), and Lp(a) declined from 29.7 to 27.1 mg/dl (P = 0.022). There were no significant differences in total, low-density lipoprotein, or high-density lipoprotein cholesterol, although the decline in triglyceride concentrations were borderline statistically significant. The distribution of apolipoprotein(a) isoforms in IDDM patients was not unusual, and the apolipoprotein(a) isoform phenotypes did not change with improved metabolic control. Lp(a) concentrations were also significantly higher than in a population-based control group of nondiabetic subjects from the San Antonio Heart Study. CONCLUSIONS: Although the number of subjects was small and the degree of improvement in metabolic control was modest, the results suggest that improved metabolic control may decrease the risk of coronary heart disease mediated by Lp(a) in IDDM.